Insiders Invested More Than $40 Million in This Stock with Major Upside Potential

: DAWN | Day One Biopharmaceuticals, Inc. News, Ratings, and Charts

DAWN – Clinical-stage biopharmaceuticals company Day One Biopharmaceuticals (DAWN) is still in its early stages of development and has yet to generate revenue. However, recent insider buying activity in the stock signals optimism about the company’s prospects and significant upside potential for its shares. So, let’s take a closer look at the stock….

Day One Biopharmaceuticals Inc. (DAWN) is a clinical-stage biopharmaceutical company focused on discovering and commercializing tailored therapeutics for patients of all ages suffering from life-threatening illnesses. The company’s lead product candidate Tovorafenib (DAY101), is an investigational oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor.

The stock recently gained traction following an insider trading activity worth more than $40 million on June 17. Shares of this $1.3-billion biopharmaceutical business have risen 18.9% since then. On June 17, Non-Executive Director Michael Gladstone and Atlas Venture Opportunity Fund II, L.P. each purchased 766,667 shares of the company’s stock at an average price of $15.00 per share.

Also, AI Day1 LLC, which controls more than 10% of DAWN, purchased 1.2 million shares for $15.00 per share. In addition, Piper Sandler raised DAWN’s price target from $35.00 to $40.00 and upgraded the company to “overweight.”

Here’s what could shape DAWN’s performance in the near term:

Latest Development

This month, DAWN released positive preliminary data from the first 22 RAO-evaluable patients enrolled in the ongoing, open-label, single-arm, pivotal Phase 2 FIREFLY-1 clinical study. FIREFLY-1 is testing tovorafenib (DAY101) as once-weekly monotherapy in patients aged six months to 25 years with recurrent or advanced pLGG, the most common brain tumor diagnosed in children, for which no licensed medicines are available, and no standard of care exists.

The data demonstrated an overall response rate (ORR) of 64% and a clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with tovorafenib monotherapy.

Strong Momentum

The company’s shares have gained 82.1% over the past three months and 7.6% over the past six months to close yesterday’s trading session at $17.90. In addition, the stock is currently trading above its 50-day and 200-day moving averages of $10.16 and $15.28, respectively, indicating an uptrend.

Impressive Earnings Estimates

Street expects DAWN’s EPS to rise 90.3% in the second quarter ending June 2022 and 56.7% in the current fiscal year.

Robust Growth

DAWN’s working capital growth of 66.5% year-over-year compares to the negative industry average of 12.1%. In addition, its year-over-year CAPEX growth of 275% is 1262.2% higher than the industry average of 20.2%.

Consensus Rating and Price Target Indicate Potential Upside

Each of the three Wall Street analysts that rated DAWN rated it Buy. The 12-month median price target of $37.50 indicates a 109.5% potential upside. The price targets range from a low of $37.00 to a high of $40.00.

Bottom Line

DAWN is an emerging company with clinical initiatives, remarkable technology, and clinical reasoning. Given analysts’ solid earnings estimates and price targets, the stock could witness further upside in the near term. In addition, the recent insider buying activities could mean better prospects ahead for the stock.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


DAWN shares were trading at $18.56 per share on Friday afternoon, up $0.66 (+3.69%). Year-to-date, DAWN has gained 10.15%, versus a -20.25% rise in the benchmark S&P 500 index during the same period.


About the Author: Pragya Pandey


Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
DAWNGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Investors: Are You Ready for November?

The S&P 500 (SPY) tumbled to end October. Is that a harbinger of more downside to come? Or will the bull market return with gusto? Investment pro Steve Reitmeister shares his time market views including a preview of his favorite stocks. Get the full story below...

3 Cybersecurity Stocks Defending Against Digital Threats

The demand for cybersecurity solutions is rising as digital threats and sophisticated cyberattacks continue to escalate. Therefore, it might be wise to keep track of cybersecurity stocks, CrowdStrike (CRWD), Palo Alto Networks (PANW), and Fortinet (FTNT), as they offer innovative solutions presenting further growth opportunities. Continue reading...

3 Oil Stocks With High Upside as Global Demand Rebounds

The outlook for oil demand growth appears promising despite economic uncertainties and worldwide supply deficit. Amid this, investing in quality oil stocks Enterprise Products Partners (EPD), Marathon Oil (MRO), and Plains All American Pipeline (PAA) could be ideal as global demand rebounds. Read more...

3 Tech Stocks Under $10 That Could Deliver Big Gains

The technology industry is booming, driven by breakthroughs and significant government investments. Thus, incorporating affordable tech stocks, Sprinklr (CXM), Sabre Corporation (SABR), and Cricut (CRCT) into your portfolio provides an accessible entry point to capitalize on the industry’s growth. Read more…

2 Concerns for Investors in October

The S&P 500 (SPY) may be touching all time highs...but recent action points to concerns on 2 fronts: inflation and earnings. Investment veteran Steve Reitmeister shares his views on these 2 timely topics along with a preview of his top stocks to buy now.

Read More Stories

More Day One Biopharmaceuticals, Inc. (DAWN) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All DAWN News